Back to Search Start Over

Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.

Authors :
Kumar SK
Callander NS
Alsina M
Atanackovic D
Biermann JS
Chandler JC
Costello C
Faiman M
Fung HC
Gasparetto C
Godby K
Hofmeister C
Holmberg L
Holstein S
Huff CA
Kassim A
Liedtke M
Martin T
Omel J
Raje N
Reu FJ
Singhal S
Somlo G
Stockerl-Goldstein K
Treon SP
Weber D
Yahalom J
Shead DA
Kumar R
Source :
Journal of the National Comprehensive Cancer Network : JNCCN [J Natl Compr Canc Netw] 2017 Feb; Vol. 15 (2), pp. 230-269.
Publication Year :
2017

Abstract

Multiple myeloma (MM) is caused by the neoplastic proliferation of plasma cells. These neoplastic plasma cells proliferate and produce monoclonal immunoglobulin in the bone marrow causing skeletal damage, a hallmark of multiple myeloma. Other MM-related complications include hypercalcemia, renal insufficiency, anemia, and infections. The NCCN Multiple Myeloma Panel members have developed guidelines for the management of patients with various plasma cell dyscrasias, including solitary plasmacytoma, smoldering myeloma, multiple myeloma, systemic light chain amyloidosis, and Waldenström's macroglobulinemia. The recommendations specific to the diagnosis and treatment of patients with newly diagnosed MM are discussed in this article.<br /> (Copyright © 2017 by the National Comprehensive Cancer Network.)

Details

Language :
English
ISSN :
1540-1413
Volume :
15
Issue :
2
Database :
MEDLINE
Journal :
Journal of the National Comprehensive Cancer Network : JNCCN
Publication Type :
Academic Journal
Accession number :
28188192
Full Text :
https://doi.org/10.6004/jnccn.2017.0023